Semaglutide is a GLP-1 receptor agonist sold as Ozempic and Wegovy, used in type 2 diabetes and obesity management. The published record on it is now large enough to separate what has been measured from what is still being argued about.
How much weight came off
A University of Alberta research team writing in The Conversation reports that GLP-1 medications reduced body weight by an average of 15 percent when used weekly for 68 weeks alongside lifestyle interventions. The same team notes that semaglutide acts on the brain to increase fullness and decrease appetite, and that weight loss is only one measure of how well the drugs work.
Why some people respond and some do not
The Alberta group is investigating whether genetics, body composition, microbiota, age and sex explain the spread in response. Their review of studies on GLP-1 therapies and energy utilization found only a few looking at resting energy use, with results they describe as neutral or inconclusive.
The brain question
Researchers from Gothenburg and Copenhagen, reviewing the evidence at the invitation of Science, report that patient record analyses have found an association between GLP-1 treatment and reduced dementia risk in people with type 2 diabetes, while cautioning that observational data cannot establish cause. In Novo Nordisk's EVOKE and EVOKE+ trials, semaglutide failed to slow progression of early Alzheimer's disease, even though several biological markers shifted.
Muscle, and what might sit alongside it
The same review flags that rapid weight loss can reduce muscle mass, a particular concern in older and physically frail patients. A UC Berkeley team testing an experimental compound called TOFA reported that obese mice lost fat without significant loss of lean mass, and that combining TOFA with semaglutide produced greater improvements in weight, glucose and triglycerides than either alone. That work is entirely in mice, and the authors say safety and effectiveness in humans are not established.
What Isn't Established
Whether semaglutide changes resting energy expenditure in people, in either direction. Whether it protects cognition in anyone, since the dementia signal is observational and the Alzheimer's trial was negative. Whether any add-on can spare muscle in humans, since the TOFA data stop at mice.
Where the evidence stands
The weight and metabolic outcomes rest on large human trials. The brain and energy-metabolism questions rest on observational data, one failed trial, and studies still recruiting.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.